行情

RDHL

RDHL

Redhill Biopharm
NASDAQ

实时行情|Nasdaq Last Sale

4.580
-0.310
-6.34%
交易中 14:35 09/20 EDT
开盘
4.750
昨收
4.890
最高
4.910
最低
4.570
成交量
64.08万
成交额
--
52周最高
11.52
52周最低
4.570
市值
2.14亿
市盈率(TTM)
-1.9930
分时
5日
1月
3月
1年
5年
RedHill (RDHL) 对 COVID-19 研究的数据不满意
RedHill (RDHL) posts preliminary top-line data from a phase II/III study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia. Stocks falls as the study fails to achieve its goal.
Zacks · 5天前
HC Wainwright & Co. 维持对 Redhill Biopharma 的买入,将目标价下调至 21 美元
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Redhill Biopharma (NASDAQ:RDHL) with a Buy and lowers the price target from $23 to $21.
Benzinga · 5天前
HC Wainwright 将 Redhill Biopharma 的目标价格从 23 美元下调至 21 美元,维持买入评级
MT Newswires · 5天前
热门股票:澳门赌局; FCEL 收益; CROX 命中率高; WEBR 设置低; RDHL 的临床数据下降
While state governments in the U.S. have largely loosened restrictions on gambling in recent years, there are reports that Macau might be taking the opposite approach. Speculation of stepped-up oversight
Seekingalpha · 5天前
午后市场更新:道指重挫 300 点;通信系统股价攀升
Toward the end of trading Tuesday, the Dow traded down 0.87% to 34,565.88 while the NASDAQ fell 0.46% to 15,035.39. The S&P also fell, dropping 0.60% to 4,441.76.
Benzinga · 5天前
CLMT、ATER 和 MTNB 处于午盘走势中
Gainers: Communications Systems (NASDAQ:JCS) +33%. BELLUS Health (NASDAQ:BLU) +20%. Matinas BioPharma (NYSE:MTNB) +19%. Onion Global (NYSE:OG) +18%. FuelCell Energy (NASDAQ:FCEL) +17%. Silverback Therapeutics (NASDAQ:SBTX) +16%. DatChat (NASDAQ:DATS) +15%....
Seekingalpha · 6天前
BELLUS Health、aTyr Pharma 领跑医疗保健赢家; Virpax Pharmaceuticals 和 RedHill Biopharma 是主要输家
Gainers: BELLUS Health (NASDAQ:BLU) +26%, aTyr Pharma (NASDAQ:LIFE) +22%, Jounce Therapeutics (NASDAQ:JNCE) +14%, NanoViricides (NYSE:NNVC) +12%, Matinas BioPharma (NYSE:MTNB) +12%. Losers: Virpax Pharmaceuticals (NASDAQ:VRPX) -37%, RedHill Biopharma (NASD...
Seekingalpha · 6天前
周二 RedHill Biopharma 的股票发生了什么变化?
Benzinga · 6天前
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解RDHL最新的财务预测,通过RDHL每股收益,每股净资产,每股现金流等数据分析Redhill Biopharm近期的经营情况,然后做出明智的投资选择。
分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测RDHL价格均价为18.44,最高价位26.00,最低价为11.50。
EPS
机构持股
总机构数: 69
机构持股: 1,109.16万
持股比例: 23.74%
总股本: 4,672.00万
类型机构数股数
增持
17
42.22万
建仓
8
27.43万
减持
15
249.58万
平仓
17
165.16万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-3.06%
制药与医学研究
-1.70%
高管信息
Chairman/Chief Executive Officer/Director
Dror Ben-Asher
Chief Financial Officer
Micha Ben Chorin
Finance Director
Einav Nagar-Brenner
Chief Operating Officer
Gilead Raday
Senior Vice President/Director of Sales/Director of Marketing
Rob Jackson
Senior Vice President
Patricia Anderson
Senior Vice President
Reza Fathi
Senior Vice President
Robert Gilkin
Senior Vice President
David Wasserman
Chief Scientific Officer
June Almenoff
Vice President - Finance
Todd Krzyzaniak
Vice President/Director of Human Resources
Michelle Snelling
Vice President
Danielle Abramson
Vice President
Aida Bibliowicz
Vice President
Ben Martie
Vice President
Shani Maurice
Vice President
Craig Miller
Vice President
Steven Thomasian
Vice President
Reginald Williams
Other/Director
Rick Scruggs
Other
Adi Frish
Other
Guy Goldberg
Independent Director
Shmuel Cabilly
Independent Director
Alessandro Della Cha
Independent Director
Alla Felder
Independent Director
Kenneth Reed
Independent Director
Eric Swenden
Independent Director
Ofer Tsimchi
暂无数据
RDHL 简况
Redhill Biopharma Ltd是一家以色列的专业生物制药公司,主要专注于胃肠道疾病和传染病业务。该公司在美国推广三种胃肠道药物:Movantik、Talicia和Aemcolo。关键临床后期产品线开发计划包括:opaganib(Yeliva)和用于多种适应症的RHB-107,包括COVID-19、RHB-204肺部非结核分枝杆菌(NTM)病和RHB-104克罗恩病。

微牛提供RedHill Biopharma Ltd (ADR)(NASDAQ-RDHL)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的RDHL股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易RDHL股票基本功能。